U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328581) titled 'BCMA-CD19 cCAR T for the Treatment of Refractory Lupus' on Oct. 17, 2025.
Brief Summary: This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19-IL-15/IL15sushi cCAR T cells in patients with relapsed and/or refractory SLE, with or without Lupus Nephritis.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus (SLE)
Lupus Nephritis (LN)
Intervention:
BIOLOGICAL: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following cyclophosphamide-only lymphodepletion
Anti-BCMA, Anti-CD19 Compound CAR-T Cells
Recruitme...